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Atherosclerotic renovascular disease (aRVD) is an increasingly recognized cause of severe hypertension and declining
kidney function. Patients with aRVD have been demonstrated to have an increased risk of adverse cardiovascular events
compared with patients without aRVD. For these reasons, >45,000 renal artery revascularization procedures are
performed annually, with significant growth observed in the number of procedures performed each year. The efficacy of
contemporary revascularization therapies in the treatment of aRVD is unproven and controversial, with no level I data to
support current practices. Lower-level data suggest that kidney function improvement is a key indicator of subsequent
improved survival free of adverse cardiovascular events and dialysis, and that observed improvements of hypertension
confer, at best, limited benefit. This review focuses on existing data on the management of aRVD, including data from
completed and ongoing randomized clinical trials. This review also examines other existing data regarding aRVD that
may guide current treatment and future research efforts into this significant clinical and public health problem until
widely accepted level I evidence emerges. ( J Vasc Surg 2009;50:1197-210.)Atherosclerotic renovascular disease (aRVD) is associ-
ated with increased cardiovascular morbidity and mortality
and is a recognized cause of severe, secondary hypertension
and impaired renal function.1-4 Atherosclerotic RVD is also a
problem increasingly encountered by practicing vascular
surgeons due to changes in patient demographics, the
increasing use of sophisticated imaging for other disease
processes, and angiography of the renal arteries during
other vascular interventions. Furthermore, the uncertain
clinical and hemodynamic significance of many lesions
identified incidentally during investigations for other dis-
ease processes make treatment decisions difficult.
Many techniques have been applied to the treatment of
aRVD, including nephrectomy, surgical endarterectomy or
bypass, and balloon angioplasty of the renal arteries (RA)
with and without stent placement (RA-PTAS), with the
goals of reducing morbidity and death related to cardiovas-
cular and renal causes. Published results and patient selec-
tion criteria have been inconsistent across techniques.
Advances in endovascular technologies have led to an ex-
ponential increase in the application of revascularization
therapies to aRVD. It is currently estimated that between
30,000 and 45,000 RA-PTAS are performed annually for
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doi:10.1016/j.jvs.2009.05.048Medicare beneficiaries in the United States,5,6 and this num-
ber is expected to grow significantly as the population ages.
This rapid increase in procedures for aRVD has occurred in
the absence of any level I data demonstrating efficacy for
revascularization therapy in terms of improving survival or
freedom from adverse cardiovascular or renal events.
An obvious question can be posed: Is this a rational use
of increasingly limited health care resources? A recent re-
view by the Agency for Healthcare Research and Quality
(AHRQ) examined all of the existing data from completed
clinical trials and prospective research evaluating aRVD and
found that “ . . . available evidence does not clearly support
one treatment approach over another for [aRVD].”7
The Medical Evidence and Coverage Advisory Com-
mittee (MedCAC) of the Centers for Medicare and Med-
icaid Services also examined this topic. That meeting dis-
cussed various proposals designed to limit physician and
hospital reimbursement for renal revascularization proce-
dures. The goal of these coverage proposals was to increase
enrollment in clinical trials and other investigations de-
signed to provide firm data allowing for rational treatment
recommendations in the future. After discussion and public
comment from physicians, professional societies, including
the Society for Vascular Surgery and American Heart Asso-
ciation, and industry, current reimbursement policies were
left intact. However, it is almost certain that these policies
will be examined again once data from currently enrolling
clinical trials are available.
This review will focus on the existing data regarding the
management of aRVD. Data from completed randomized
clinical trials (RCTs) and trials currently underway will be
discussed. It will also examine other existing data regarding
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into this significant clinical and public health problem.
PROSPECTIVE NON-RCT DATA
Prevalence and natural history. Although aRVD is
relatively uncommon in the general population, the esti-
mated prevalence among elderly individuals is approxi-
mately 7%.8 In addition to age, other conditions associated
with an increased prevalence of aRVD include chronic
kidney disease, hypertension, peripheral vascular disease,
aortic aneurysm, acute renal failure, congestive heart fail-
ure, and coronary artery disease.9-14 An increasing preva-
lence of aRVD among elderly patients beginning renal
replacement therapy was also demonstrated in a recent
cross-sectional report,14 and a continuing increase in pa-
tients with identified aRVD requiring interventional or
medical management, or both, can be expected.
Data about the anatomic progression of aRVD have
been derived from multiple patient cohorts, defined by
presence of anatomically identified aRVD,15,16 aRVD with
severe hypertension or ischemic nephropathy,17-19 the
presence of associated aortic or peripheral vascular dis-
ease,18,20 need for cardiac catheterization,9 or age and
demographic criteria.21 Anatomic progression has been
variably defined among these studies, with the greatest rates
of progression noted in retrospective angiographic studies
and in studies of individuals selected for surveillance with
severe hypertension or renal insufficiency, or both, who
were deemed inoperable.20,22-24 More recent series have
reported anatomic progression among 8% to 31%
of patients and progression to occlusion in 0% to
7%.9,15,16,19,21,25,26 These comparatively lower rates of
disease progression likely reflect the effects of concomitant
risk factor management using contemporary strategies and
the surveillance of more “physiologically insignificant” le-
sions.
Progression of aRVD can also be considered from a
functional perspective. Surrogate end points used to assess
functional disease progression have included renal length,
serum creatinine values, estimated glomerular filtration rate
(eGFR), and blood pressure. Using ultrasound-based
follow-up of patients with aRVD and hypertension, Caps et
al19 observed a 2-year incidence of renal atrophy, defined as
reduction in renal length of1cm, of 5%, 12%, and 21% in
kidneys with baseline stenosis categorized as normal,
60%, and 60%, respectively. Zierler et al16 noted a
similar association between hemodynamic severity of
aRVD and subsequent decline in kidney size, although this
decline in length was not accompanied by a significant
change in serum creatinine levels.
Other descriptions of the longitudinal relationships
between anatomic aRVD, blood pressure, and renal func-
tion have also been reported. In their analysis of the Car-
diovascular Health Study cohort, Pearce et al21 observed a
significant association between incident ultrasound-defined
aRVD and longitudinal increases in both blood pressure
and serum creatinine values; similar associations, however,
were not detected for anatomic progression of baselineaRVD in this largely asymptomatic cohort.21 Anatomic
progression of RVD is therefore not consistently accompa-
nied by a decline in renal function or progression in severity
of hypertension.
The natural history of aRVD thus appears to be char-
acterized by anatomic progression in a minority of patients,
most of which do not progress to renal artery occlusion.
Consideration of the natural history of aRVD is particularly
relevant to the management of hemodynamically insignifi-
cant aRVD and significant anatomic aRVD without clinical
manifestations. Hemodynamically insignificant renal artery
lesions are frequently identified in patients with severe
hypertension or renal function impairment, or both, who
undergo diagnostic imaging because of clinical suspicion.
Furthermore, expanding use of both angiography using
computed tomography and magnetic resonance imaging
(MRI), as well as “drive by” angiography,27 have led to
another increasingly common scenario where intervention
is undertaken for incidentally discovered aRVD.
Intervention for a renal artery lesion that is not associ-
ated with clinical sequelae or is insufficient to significantly
impair renal perfusion may be termed “prophylactic,” and
such an approach presumes that the identified stenosis will
progress to cause adverse effects if managed conservatively.
Prophylactic renal artery intervention further presumes that
the natural history of the renal artery after the intervention
is superior to that of the stenotic renal artery treated with
appropriate medical management in the absence of proce-
dural intervention, and that disease progression causes loss
of renal function that cannot be fully retrieved.
Given these considerations, along with the lack of a
consistent relationship between anatomic disease severity
and subsequent development of renal dysfunction or hy-
pertension, current evidence is inadequate to support pro-
phylactic renal artery revascularization. Furthermore, it is
likely that most of the currently performed interventions
for aRVD are in this prophylactic category. We, therefore,
support a conservative, nonoperative management strategy
for patients with aRVD, normal renal function, and well-
controlled hypertension.
Medical management
The management of aRVD consists of medical therapy
alone or combined with revascularization. Aggressive med-
ical therapy constitutes adequate treatment for most pa-
tients and should be implemented before any consideration
of a procedural intervention. Goals of medical therapy
include blood pressure control and prevention of renal
function decline as well as therapy to prevent secondary
cardiovascular disease events, including smoking cessation.
Much of the evidence supporting current strategies for
medical management comes from studies conducted on
patient populations defined by hypertension, chronic kid-
ney disease, coronary artery disease, heart failure, or diabe-
tes rather than aRVD.
Angiotensin-converting enzyme inhibitors and re-
ceptor antagonists. The central role of angiotensin II in
the pathophysiology of aRVD makes inhibition of the
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 5 Edwards and Corriere 1199renin-angiotensin-aldosterone system a logical therapeutic
target, and angiotensin-converting enzyme (ACE) inhibi-
tors or AT1R blockers (angiotensin receptor blockers
[ARBs]), or both, indeed comprise a mainstay of current
medical therapy for control of hypertension, preservation of
renal function, and reduction in risk of cardiovascular mor-
bidity and death. ARBs have similar cardiovascular effects,
antihypertensive efficacy, and a favorable side effect profile
compared with ACE inhibitors.28
Prospective RCTs in patients with cardiovascular dis-
ease and heart failure have demonstrated reductions in total
mortality, cardiovascular mortality, and major cardiovascu-
lar events associated with use of ACE inhibitors.29-34 Re-
gression of left ventricular hypertrophy has also been ob-
served in patients with essential hypertension treated with
ACE inhibitors or ARBs,35,36 with the effect observed
thought to be in excess of being explained solely by blood
pressure response.37-40 Renoprotective effects of ACE in-
hibitors among patients with diabetic and non-diabetic
nephropathy have also been demonstrated in several pro-
spective RCTs, with up to a 50% reduction in progression
of baseline renal insufficiency.41-46
This freedom from decline in renal function is a poten-
tial advantage of ACE inhibitor-based management vs
other hypertensive regimens.47 Acute renal failure has been
reported, though, after initiation of ACE inhibitor or ARB
therapy in patients with critical renal artery stenosis, partic-
ularly those with bilateral stenosis.48,49 In their retrospec-
tive study of patients with acute renal failure associated with
use of ACE inhibitors, Wynckel et al50 identified hypovo-
lemia (most frequently related to diuresis or acute gastro-
intestinal fluid loss) as the most common factor predispos-
ing to renal failure, whereas bilateral renal artery stenosis
was a less frequent etiology.
Acute deterioration in renal function after initiation of
an ACE inhibitor or ARB should therefore prompt suspi-
cion of renal artery stenosis, and these medications should
be used with caution in the setting of known bilateral
critical aRVD. Although fear of acute renal failure induced
by ACE inhibitors or ARBs has led to reluctance among
many medical practitioners to use these agents in patients
with aRVD, this complication is uncommon, and these
medications remain a key component of medical manage-
ment due to their survival and renal function benefits. In
nonrandomized studies of patients with aRVD, Losito et
al51,52 observed significant increases in survival associated
with use of ACE inhibitors. The use of ACE inhibitors was
also associated with a protective effect against serum creat-
inine increase, although not against ultimate progression to
end-stage renal disease.52
Statins. The 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors, collectively known as statins, are com-
petitive inhibitors of the rate-limiting enzyme for choles-
terol formation. Statin use has been demonstrated to pre-
vent cardiovascular death, coronary heart disease, and
myocardial infarction in patients with vascular disease, vas-
cular disease risk factors, and in patients who require non-
cardiac vascular surgery.53-57 Associations between statinuse and amelioration of declining renal function has also
been reported in selected populations.58-66 Beneficial ef-
fects observed with statin therapy occur before detectable
changes in serum cholesterol after initiation of therapy.
Evidence supporting statin use in patients with athero-
sclerosis, hypertension, renal dysfunction, or hyperlipid-
emia is generally applicable to the management of patients
with aRVD, who have atherosclerosis by definition and a
high prevalence of these other comorbid conditions com-
pared with the general population. As with other classes of
medications, however, few studies have directly assessed
outcomes associated with statin use in patients with aRVD.
In their retrospective analysis of 79 patients with aRVD,
Cheung et al67 reported a 72% reduction in relative risk for
angiographic progression of aRVD among patients treated
with a statin, although statin use was not associated with a
significant effect on change in eGFR. Among patients in
this study with angiographic evidence of anatomic disease
regression, 83% were using statins. Regression of aRVD on
statin therapy has also been reported by others,68 and these
observations are consistent with beneficial statin effects also
described for native coronary, carotid, and lower extremity
atherosclerotic disease.69-71 Statin use is associated with
improved anatomic outcomes after carotid72 and lower
extremity73 revascularization, and recent data presented by
our group have also demonstrated a profound protective
effect against restenosis after RA-PTAS.74
Other medications. The renoprotective effects of
ACE inhibitors and ARBs make them the first-line agent of
choice in the management of aRVD, but other antihyper-
tensive agents are frequently required when hypertension is
difficult to control. Diuretics, -blockers, and calcium
channel blockers are frequently used, and choice of a par-
ticular agent can be guided by patient comorbidities as well
as cost.
Antiplatelet medications are also frequently prescribed
for patients with aRVD to reduce the risk of adverse car-
diovascular events associated with atherosclerosis.75 Al-
though specific benefits of antiplatelet therapy in the med-
ical management of patients with aRVD have not been
demonstrated, aspirin or clopidogrel, or both, are impor-
tant components of periprocedural and postprocedural
management in patients undergoing renal artery revascu-
larization, particularly those managed with RA-PTAS.
Angioplasty causes a focal intimal injury that results in
luminal platelet adhesion, and use of antiplatelet medica-
tions is associated with freedom from stent thrombosis in
the coronary circulation.76-78 Antiplatelet medication is
also routinely used after renal artery revascularization, and
some evidence suggests that it may reduce procedure-
related atheroembolism if initiated before RA-PTAS.79,80
Our group has previously reported a reduction in the
number of embolic particles captured during protected
RA-PTAS and improved early postoperative eGFR associ-
ated with preoperative aspirin use.79 Although the rationale
for antiplatelet therapy among patients undergoing renal
artery revascularization is generally supported by these
findings in combination with results in the coronary circu-
on.
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platelet regimen.
Endovascular management
Primary angioplasty is currently considered appropriate
endovascular management for renal artery fibromuscular
dysplasia; however, superior technical success has been
demonstrated for primary stenting in the management of
ostial aRVD.81-83 Contemporary endovascular manage-
ment of aRVD therefore consists of RA-PTAS and RA-
PTAS has been recommended as the primary initial mode
of intervention in aRVD.84 Table I85-97 summarizes out-
comes associated with RA-PTAS performed for aRVD from
studies reported since 2000 that included 50 pa-
tients.81,82,85-91,93-95,97-114,115 Periprocedural morbidity
was 2% to 18% and mortality was 0% to 2%. Most of the
perioperative complications were related to access-site he-
matomas or bleeding.
Comparison of hypertension and renal function re-
sponses between these studies is difficult due to the heter-
ogeneous nature of baseline patient factors or indications,
or both, for revascularization. Although a limited number
of studies have described improved renal function as the
most frequent categoric response to RA-PTAS,88,91,110,115
postintervention renal function for most patients is un-
changed or worsened. Several authors have observed postint-
ervention decline in renal function with equal or greater
frequency than improvement.81,86,87,90,94,100,102,106,107,112
Cure of hypertension after RA-PTAS is rare (Table I), with
most patients categorized as being improved. More recent
publications in the era of more aggressive ACE inhibitor
and ARB use, though, demonstrate lower rates of hyper-
tension improvement.97,116 Furthermore, anatomic and
functional responses do not appear to be particularly dura-
Table I. Endovascular renal artery revascularization with a
First author Year Patients
Bilateral
treatment,
%
Pre-op renal
dysfunction,
%
Ren
Improve
Burket85 2000 127 NR 29 43
Lederman86 2001 300 41 37 9
Bush87 2001 73 16 68 23
Rocha-Singh88 2002 51 55 100 77
Kennedy89 2003 261 NR 36 61
Gill90 2003 100 26 75 31
Zeller91 2003 215 23 52 52
Henry92 2003 56 14 32 14
Zeller93 2004 456 NR 52 34
Nolan94 2005 82 NR 59 23
Kayshap95 2007 125 36 100 42
Holden96 2006 63 32 100 97
Corriere97 2008 99 11 75 28
Mean %b 30 55 31
NR, Not reported.
aSeries selected based on publication in 2000 or later, use of angioplasty and
and/or hypertension responses.
bWeighted mean based on number of patients with reported data categor
categoric response categories were combined were not included in calculatible over time.117,118Postintervention decline in renal function is a serious
complication for patients treated with RA-PTAS, especially
those with ischemic nephropathy. Several potential expla-
nations for this observed deterioration have been advanced,
including contrast nephropathy and atheroembolization at
the time of the procedure. By comparison, patients with
normal renal function treated with RA-PTAS for renovas-
cular hypertension have no potential for renal function
improvement and risk procedurally associated renal func-
tion deterioration, while the hypertension benefit gained
through intervention is most likely to be modest.
Several studies have therefore attempted to identify
clinical predictors of renal function and hypertension re-
sponses to RA-PTAS, which would permit selective appli-
cation of this revascularization technique to those most
likely to receive benefit. Associations with renal function
response to RA-PTAS have been described for bilateral
aRVD,119 bilateral intervention,93 elevated baseline serum
creatinine,91,93,120 rapid preintervention decline in renal
function,95 and impaired left ventricular function.91 De-
scribed associations with blood pressure response to RA-
PTAS include bilateral disease,113 elevated preoperative
brain natriuretic peptide,121 female gender,91 degree of
renal artery stenosis,114 and severity of preoperative hyper-
tension.91,93,113,114
Stabilization of renal function after RA-PTAS has been
described in several retrospective studies.88,95,103,120How-
ever, these studies lack randomized comparisons with pa-
tients managed medically and apply the concept of renal
function “stabilization” to a variety of scenarios, including
cessation of decline in eGFR, reduction in the rate of eGFR
decline, or the absence of subsequent decline in eGFR in
patients with aRVD and normal baseline renal function.
Although the prevention of additional decline in renal
plasty and stentinga
ction response, % Hypertension response, %
Peri-op outcome,
%
nchanged Worsened Cured Improved Failed Death Morbidity
57 NR 2 4
78 14 70 30 1 2
51 26 NR 1.4 9
18 5 91 9 0 14
39 NR NR NR
38 31 4 79 17 2 18
48 76 24 0 5
66 0 18 59 23 1.8 NR
39 27 46 54 1 NR
53 24 NR 81 NR 0 7
23 25 NR 1.6 6
3 0 55 45 NR NR
65 7 1 21 78 0 5.5
38 31 18 54 28 1 6.2
g, and inclusion of50 patients, and categorical reporting of renal function
ccording to column headings; references where data was not reported orngio
al fun
d U
stentin
ized afunction in patients experiencing rapid deterioration may
on.
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important to remember that only recovery of renal function
(rather than avoidance of additional decline) has been
demonstrated to improve dialysis-free survival after renal
revascularization and that acute functional decline is detri-
mental.95,122,123
Considering the natural history of aRVD with-
out intervention, as previously discussed, the potent-
ial for a decline in renal function after RA-PTAS, and
the 11% to 38% rate of recurrent stenosis after
RA-PTAS,82,83,86,87,94,97,100,104,107,109-111,113,124 curr-
ently available evidence provides no justification for RA-
PTAS for the avoidance of future renal dysfunction in
patients with aRVD whose baseline renal function is unim-
paired. These referenced data have also led our group to
focus primarily on declining renal function as the major
indication for renal artery revascularization.
Surgical management
Surgical revascularization of the renal artery is now an
infrequently applied technique but one that continues to
have an important place in the interventional armamentar-
ium given its superior durability. Aortorenal bypass and
renal artery thromboendarterectomy are two of the most
commonly used techniques for surgical renal artery revas-
cularization. Alternative methods include reimplantation
and extra-anatomic bypass, such as hepatorenal, splenore-
nal, or iliorenal bypass. Surgical renal artery reconstruction
using these techniques may also be combined with repair of
concomitant aortic disease. Unfortunately, an in-depth dis-
cussion of these various methods for renal artery revascu-
larization is beyond the scope of this review.
Table II122,125-130 summarizes outcomes associated
with surgical renal revascularization from selected retro-
spective cohort analyses. It is important to remember that
these reviews likely report results from a different popula-
tion of patients than the corresponding angioplasty data
Table II. Selected series of surgical renal artery revascular
Reference Year Patients
Bilateral
repair, %
Pre-op renal
dysfunction,
%
Renal
Improved
Fergany125b 1995 175 2.3 92.3 35
Cambria126 1996 139 13 77 73
Darling127 1999 568 18 NR 26
Hansen122 2000 232 64 100 58
Paty128 2001 414 NR 4 97
Cherr129 2002 500 59 48.8 43
Marone130 2004 96 27 100 42
Mean %b 31 38 38
NR, Not reported.
aRenal function and hypertension responses expressed percentage of patie
inclusion of 50 patients, and categoric reporting of renal function and/or
bWeighted mean based on number of patients with reported data categori
categoric response categories were combined were not included in calculatidue to geographic variations in practice, the stigma at-tached to surgery by patients and some health care provid-
ers, and the biases applied by individual surgeons in select-
ing patients for surgery vs RA-PTAS.
The perioperative mortality rate after surgical revascu-
larization is 3% to 8%. Thesemortality figures may not apply
to lower-volume centers. Data from the National Inpatient
Sample demonstrate overall United States mortality of 10%
for surgical renal revascularization; however, that report did
not exclude those patients undergoing concomitant proce-
dures such as aneurysm repair or aortofemoral bypass at the
same time.131 Perioperative complications occur in 7% to
30% of patients undergoing surgical repair. The most fre-
quently observed complications include myocardial infarc-
tion, stroke, arrhythmia, pneumonia, and renal failure.
Local complications requiring repeat exploration have been
associated with increased postoperative serum creatinine lev-
els,130 and perioperative graft thrombosis is recognized in 0%
to 7% of patients.125,127,130,132,133 Intraoperative comple-
tion renal artery duplex ultrasound imaging can be used to
confirm technical adequacy and reduce the risk of early
graft thrombosis. B-scan defects recognized in this manner
have led to revision of the renal artery repair in 12% of
patients undergoing surgical revascularization for ischemic
nephropathy at our center.122
Surgical renal revascularization is followed by early
improvement in postoperative renal function in 26% to 58%
of patients and worsened function in 3% to 27%. Perioper-
ative initiation of hemodialysis was required in 4% of pa-
tients described by Cambria et al,126 with half of those
patients requiring long-term renal replacement therapy.
Conversely, hemodialysis initiated for rapid preoperative
decline in renal function has been discontinued in one-
third or more of highly selected patients after surgical
revascularization.122,126,129,130 Hansen et al134 observed
reported discontinuation of hemodialysis in 16 of 20 highly
selected patients after surgical renal artery revasculariza-
tion. Bilateral or complete renal revascularization was asso-
na
on response, % Hypertension response, %
Perioperative
outcome, %
anged Worsened Cured Improved Failed
Death,
%
Morbidity,
%
47 18 46 54 0 2.9 NR
27 8 71 21 8 7.2
68 6 NR 5.5 15.9
35 7 11 76 13 7.3 30
3 NR 5.5 11.4
47 10 73 12 15 4.6 16
41 16 NR 4.1 NR
47 14 12 73 15 5.4 21
rviving operation. Series selected based on publication in 1995 or later,
rtension responses.
cording to column headings; references where data were not reported orizatio
functi
Unch
nts su
hype
zed acciated with dialysis discontinuation in this series and has
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with preoperative renal dysfunction not requiring dialy-
sis.122 Associations with long-term renal function improve-
ment after surgical revascularization observed byMarone et
al130 included preoperative initiation of hemodialysis and
early postoperative creatinine improvement, whereas pre-
operative renal artery occlusion was negatively associated
with long-term renal function outcomes.
Dialysis-free survival after surgical renal revasculariza-
tion is reported at between 52% and 69% at 5 years. Positive
associations with long-term dialysis-free survival have been
described for blood pressure cured and early improvement
in serum creatinine levels. Negative associations include
diabetes, impaired baseline preoperative renal function,
renal artery occlusion at the time of repair, and early post-
operative renal function response that was either un-
changed or worsened.122,126,129,130 Hypertension re-
sponses have varied considerably between series, with most
patients categorized as improved or, less commonly, cured
in the early postoperative period.
As mentioned previously, aRVD is present in 20% to
40% of patients with aortic disease studied with angiogra-
phy,9,13,135,136 and renal artery revascularization can be
performed with exposure similar to that required for surgi-
cal management of an aortic aneurysm or occlusive disease.
Combined repair of an abdominal aortic aneurysm and
renal artery stenosis is associated with a perioperative mor-
tality rate of 0% to 7%, postoperative improvement in hyper-
tension in 18% to 86%of patients, and renal function improve-
ment in 14% to 57% in the most recent series.137-145
Although combined repair in the absence of severe
hypertension or renal dysfunction can be performed with
lowmorbidity and mortality,141 the addition of renal artery
revascularization to aortic aneurysm repair has been associ-
ated with increased perioperative mortality in retrospective
comparisons.140,146 Postoperative renal failure requiring
hemodialysis has been noted in 2% to 18% of patients
undergoing combined repair, and postoperative decline in
renal function has been observed more frequently than
improvement in some cohorts.138,145 Patients with normal
renal function who are normotensive or have well-
controlled hypertension therefore are potentially placed at
increased risk for perioperative death or renal failure, or
both, when renal revascularization is added to aortic repair,
without any prospect for improvement in blood pressure or
renal function as a result of renal intervention.
Given these considerations, we favor selective com-
bined repair for patients with hemodynamically significant
aRVD in the setting of severe hypertension or renal dys-
function, or both.147 This approach is supported by the
findings of Williamson et al,148 who did not detect any
associations between high-grade aRVD and long-term sur-
vival, need for dialysis, or serum creatinine level among 171
asymptomatic patients undergoing aortic aneurysm repair
without renal intervention. When juxtarenal or suprarenal
abdominal aortic aneurysm repair is associated with risk of
renal artery occlusion due to factors such as clamp proxim-
ity or adjacent plaque burden, the addition of renal arteryrepair in the absence of critical stenosis may be considered
in select patients. Similarly, RA-PTAS may be used as an
adjunct to endovascular abdominal aortic aneurysm repair
if anatomic factors place the patient at increased risk for
procedure-related renal artery occlusion, although evi-
dence supporting such strategies is limited.
CLINICAL TRIAL DATA
Completed trials
Seven RCTs have completed enrollment and reported
results on the management of aRVD. Three trials com-
pared balloon angioplasty withmedical management alone,
one compared primary renal artery stenting with balloon
angioplasty with stenting as needed, two compared surgical
revascularization with endovascular revascularization, and
one compared surgical revascularization with medical man-
agement. In six of the seven trials, the primary end points
were blood pressure control or renal artery patency. These
trials are summarized in Table III.81,149-153
None of the three completed trials comparing angio-
plasty with medical management have demonstrated blood
pressure, renal function, or survival results favoring renal
artery angioplasty when the entire study group was evalu-
ated in an intention-to-treat analysis. The report by the
Scottish Newcastle group did, however, demonstrate a
significant advantage in blood pressuremanagement for the
subset of participants with bilateral aRVD.26 Van Jaarsveld
et al,151 in their trial of 106 patients, demonstrated signif-
icant reduction in blood pressure and medications in post
hoc analyses of treatment received, ignoring initial treat-
ment assignment and crossover status. In a recent update,
this same group reported that the reduction in medications
did not result in any discernible increase in health-related
quality of life.154
All of these trials were relatively small and significantly
underpowered to detect meaningful differences in “hard”
outcomes such as survival, freedom from adverse cardiovas-
cular events, and the development of dialysis-dependent
renal failure. Furthermore, the study excluded patients with
severe baseline renal function impairment,26,151 suffered
from extensive crossover between treatment groups,150,151
did not incorporate renin-angiotensin-based antihyperten-
sive agents into medical management,26 and used angio-
plasty without stenting for procedural management.26,149-151
These limitations make it impossible to generalize results
from these trials to contemporary endovascular manage-
ment of aRVD.
In a separate trial comparing primary renal artery stent-
ing vs angioplasty alone, Van de Ven et al81 evaluated
disease recurrence at 6 months in patients with ostial renal
artery stenosis randomized to angioplasty alone vs RA-
PTAS. They reported superior technical success, improved
primary patency, and reduction in recurrent stenosis in the
group treated with RA-PTAS. These results contributed to
widespread incorporation of primary stent placement as the
standard contemporary endovascular treatment for aRVD.
nine; R
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ization have also been reported. In their comparison be-
tween angioplasty (without stenting) vs surgical revascular-
ization of aRVD, Weibull et al149 observed similar
hypertension and blood pressure responses between groups
but inferior technical success and primary patency with
endovascular management. Of the patients undergoing
angioplasty in this study, 17% subsequently required sur-
gical intervention. The authors recommended angio-
plasty combined with aggressive follow-up and repeat
intervention as the management strategy of choice. Sim-
ilar results have also been reported by Balzer et al153 in
terms of patency, hypertension, and renal function re-
sponses.
A single randomized comparison between surgical
Table III. Randomized trials of intervention for atheroscl
Reference (year) Patients Design
Primary
outcome(
Weibull149
(1993)
58 Hypertensive patients
randomized to
angioplasty vs
surgical
reconstruction
Patency (24 m
Webster26
(1998)
55 Hypertensive patients
randomized to
angioplasty vs
medical therapy
BP, Cr (6 mo
Plouin150
(1998)
49 Hypertensive patients
randomized to
angioplasty vs
medical therapy
24-h ambula
BP (6 mon
Van de Ven81
(1999)
87 Patients with ostial
RA stenosis
randomized to
angioplasty vs
angioplasty and
stenting
Restenosis (6
mon)
Van Jaarsveld151
(2000)
106 Hypertensive patients
randomized to
angioplasty vs
medical therapy
BP (1 y)
Uzzo152 (2002) 52 Patients with RA
stenosis affecting
bilateral kidneys,
solitary kidney, or
unilateral kidney
with azotemia
randomized to
medical vs surgical
therapy
Event-free
survival
Balzer153
(2009)
49 Patients with 70%
RA stenosis
randomized to
surgery or renal
artery angioplasty
stenting
Patency
aRVD, Atherosclerotic renal vascular disease; BP, blood pressure; Cr, creatiand medical management of aRVD has also been pub-lished. Uzzo et al152 randomized 52 patients to medical
therapy vs surgical intervention and assessed a composite
end point outcome that included blood pressure, renal
function, cardiovascular morbidity, and death. Patients
selected for randomization in this single-center trial had
bilateral renal artery stenosis, renal artery stenosis affect-
ing a solitary kidney, or unilateral renal artery stenosis in
the setting of renal dysfunction. Operative management
was heterogeneous but was conducted by a single sur-
geon. Medical management was also directed by a single
individual, but incompletely described. The authors
found no significant difference in event-free survival
between treatment groups at a median follow-up of 74
months, but did note a trend towards decreased mor-
tality in patients with renal insufficiency treated surgi-
c renal artery stenosis
Findings Comments
Improved primary patency
associated with surgical
reconstruction
Patients with diabetes, age 70 y,
Cr 300 mmol/L, or bilateral
disease excluded. 17% of
patients randomized to
angioplasty later had surgical
intervention.
No significant difference
between angioplasty
and medical therapy at
6 months
Post hoc analyses demonstrated
BP benefit for patients with
bilateral aRVD treated with
angioplasty
No difference in mean
blood pressure between
groups at termination
7 patients randomized to medical
treatment crossed over to
angioplasty group due to
refractory hypertension; 2 of 23
patients in angioplasty group
also had stent placement.
Angioplasty and stenting
associated with
increased technical
success, improved
primary patency, and
lower rate of restenosis
No differences in hypertension or
renal function responses
between groups
No significant difference
between angioplasty
and medical therapy at
3 or 12 mon
22 patients randomized to
medical treatment crossed over
to angioplasty at 3 mon
No significant difference
in event-free survival
between groups (overall
median follow-up, 74
mon)
Combined event outcome
included BP, renal function,
cardiovascular morbidity, and
death. Medical therapy
undefined. Patients with renal
insufficiency demonstrated
improved survival if treated
surgically.
No significant differences
in primary patency,
hypertension, or renal
function responses
Both treatment groups had
improvement in hypertension
and renal function. No
morbidity or mortality benefit
to RA-PTAS. Analysis was by
treatment, not
intention-to-treat.
A-PTAS, renal artery percutaneous transluminal angioplasty and stenting.eroti
s)
on)
n)
tory
)cally.
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itations: outdated endovascular technology was used,149
medical treatment was incompletely described,152,154 or
statistical power was severely limited to assess meaningful
survival and freedom from event outcomes.149,152,154
These trials149,152 were assessed as having poor quality data
by the AHRQ review and in the compendium of data
examined by the MedCAC.
Ongoing trials
Five clinical trials comparing RA-PTAS vs best medical
therapy are currently awaiting completion or peer-reviewed
reporting of results, or both: the Renal Atherosclerotic
reVascularization Evaluation (RAVE),155 theNephropathy
Ischemic ThERapy (NITER),156 the benefit of STent
Placement and Blood Pressure and Lipid-Lowering for the
Prevention of Progression of Renal Dysfunction Caused by
Atherosclerotic Ostial Stenosis of the Renal Artery
(STAR),157 the Angioplasty, and Stent for Renal Artery
Lesions (ASTRAL),158 and the Cardiovascular Outcomes
in Renal Atherosclerotic Lesions (CORAL) trials.159
RAVE, NITER, and STAR anticipate randomization of
150 patients each. ASTRAL and CORAL are larger,
multicenter trials with planned enrollments of 750 and
1080 participants, respectively.
ASTRAL is a trial comparing best medical management
vs RA-PTAS in patients with identified aRVD and for
whom the treating physicians are uncertain that revascular-
ization will be beneficial. This latter criterion inserts un-
avoidable selection biases into the trial because enrolling
physicians are nearly certain to have differing opinions on
the benefits of revascularization and the trial (by design)
excludes those patients most likely to benefit from inter-
ventional therapy. As such, ASTRAL may therefore be
most relevant to evaluating the practice of empiric or
prophylactic RA-PTAS. ASTRAL has completed enroll-
ment of 806 patients with a mean serum creatinine level of
2 mg/dL and a mean severity of renal artery stenosis of
75%, although a significant subset had lesions not likely to
be hemodynamically significant. Technical success was
achieved in 88% in the intervention group, and no signifi-
cant differences were observed at the 12-month follow-up
in serum creatinine level, freedom from adverse events
(including myocardial infarction, stroke, congestive heart
failure, angina, or need for coronary artery bypass grafting/
percutaneous coronary intervention), or death compared
with patients who received best medical management. It is
important to note, though, that these reports are prelimi-
nary and that peer-reviewed results are not yet available.
CORAL represents the largest and most scientifically
rigorous of the contemporary clinical trials examining
aRVD. CORAL is an RCT comparing an arm of detailed and
thorough best medical management and an arm of medical
management plus RA-PTAS. CORAL has currently en-
rolled 646 participants with significant hypertension re-
quiring two or more drugs for control or renal insufficiency
(eGFR 60 mL/min), or both, in the setting of aRVD.
Completion of enrollment is anticipated in the next 24months. CORAL is the most likely of the existing trials to
provide meaningful data on the efficacy of RA-PTAS.
However, it is also possible that the fairly broad inclusion
criteria for the trial, which are necessary to recruit and
enroll sufficient patient numbers, will result in an overall
negative result and potentially obscure a finding of efficacy
for more severely affected participants. Hopefully, a suffi-
cient number of such participants will be included to allow
for meaningful subset analyses to avoid this potential type
II error.
OUTCOME IMPROVEMENT EFFORTS
Patient selection. Given the tremendous variability in
results from the treatment of aRVD by any means, the
appropriate selection of patients most likely to benefit from
revascularization would greatly enhance the results. Clini-
cal criteria have been used to predict functional responses
to revascularization, including bilaterality of aRVD, rapid
preintervention decline in renal function, severe uncontrol-
lable preoperative hypertension, absence of proteinuria,
and the presence of cardiac disturbance syndromes such as
flash pulmonary edema. These criteria are certainly useful in
selecting subgroups likely to receive benefit from revascu-
larization, but such patients represent a minority of those
considered for intervention.
Other, more quantifiable methods have also been ex-
amined for their predictive abilities in the management for
aRVD, such as renography with various pharmacologic
adjuncts,158-163 renal vein renin levels,164-166 and split
function renal solute excretion.167 Unfortunately, none of
these modalities have proven to be reproducibly accurate
prognosticators of outcome. More recently, though, atten-
tion has turned to Doppler ultrasound imaging and MR-
derived measures as potential predictors of functional re-
sponse to revascularization.
In 2001 Radermacher et al168 reported a series of 131
successful RA-PTAS procedures and the relationship be-
tween hypertension and renal function responses and the
intrarenal resistive index (RI). RI was measured from intra-
renal measurements of velocity and calculated as RI [1 –
(end diastolic velocity/peak systolic velocity)] 100. RI is
postulated to represent a surrogate marker of high paren-
chymal resistance to blood flow as a result of irreversible
loss of functional renal tissue. They reported that an RI of
0.8 predicted poor functional responses after RA-PTAS
with great accuracy.168 This prognostic measure was
quickly adopted as a surrogate for irreversible parenchymal
disease and even incorporated into consensus management
guideline documents and inclusion/exclusion criteria for
clinical trials. Unfortunately, other authors have not been
able to reproduce these results,169-171 and the utility of the
RI remains unproven.
More recently, a pilot study of blood oxygen level–
dependent MRI has shown promise in detecting irretriev-
able parenchymal mass distal to aRVD.172 That report
detailed differences in baseline R2-MRI-measured oxygen
levels and changes in oxygenation after a furosemide/
solute challenge in normal-appearing vs atrophic kidneys
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tested directly in predicting responses after renal revascu-
larization but it certainly appears to hold promise.
In summary, no current single test or battery of tests
can accurately predict a patient’s response to renal artery
revascularization. This fact underscores the importance of
careful patient selection and attention to those factors
associated with positive responses in making the choice to
intervene for each individual patient.
Procedural modifications. In addition to identifica-
tion of factors associated with favorable clinical response,
recent efforts to improve outcomes associated with RA-
PTAS have also included attempts to improve renal func-
tion responses through prevention of procedurally related
atheroembolization. Clinical and in vitro data have demon-
strated that atheroembolism is common during RA-
PTAS92,173,174 and is associated with worsened eGFR re-
sponse.79 Filter or balloon occlusion devices have been
used to prevent distal atheroembolization during catheter-
based intervention in the carotid and coronary circulations,
and devices designed for use in these locations have been
used for embolic protection during RA-PTAS.175
It is important to note, however, that the genesis of
atheroembolic debris liberated during RA-PTASmay differ
substantially from the same process in the carotid and
coronary circulations. Nonetheless, compared with histor-
ical results of conventional (unprotected) endovascular re-
nal artery intervention, initial reports of patients treated
with RA-PTAS and distal embolic protection have de-
scribed a relatively lower frequency of postintervention
decline in renal function (0% to 5%) and a greater frequency
of postintervention improvement.79,92,96,173,176-178 Hy-
pertension responses, perioperative morbidity, and periop-
erative mortality from these series are similar to those
observed with unprotected RA-PTAS.
These nonrandomized results are encouraging and
seem to support the use of distal embolic protection during
RA-PTAS. Further data from RCTs will be necessary,
though, before embolic protection can be definitively rec-
ommended for use during RA-PTAS. The only existing
randomized evaluation of distal protection to date demon-
strated benefit for the use of the Angioguard device (Cor-
dis, Miami Lakes, Fla), but only if used in combination with
abciximab, a glycoprotein IIb/IIIa antagonist.80 Use of
the Angioguard device alone was not beneficial and was
actually associated with an overall decline in renal function
during follow-up. Further studies are necessary to better
define this question of technique for RA-PTAS.
CONCLUSIONS
The treatment of aRVD remains controversial for many
reasons:
● Existing RCT data have demonstrated no benefit for
the application of renal artery revascularization for
aRVD; however, the studies were severely limited by
participant numbers, antiquated techniques, selectionof patients unlikely to benefit, and other methodologic
flaws.
● Despite the lack of controlled data, experience and
noncontrolled data indicate that many patients do
indeed benefit from renal artery revascularization, of-
ten in profound ways.
● Intervention for blood pressure control (the dominant
indication for most currently applied interventions)
alone appears to be unrewarding except in those cases
of truly uncontrollable hypertension or hypertension
complicated by flash pulmonary edema or other acute
clinical sequelae.
The controversy will persist until sound data from
rigorously conducted RCTs are available, and quite likely
beyond. Until additional data are available, appropriate
patient selection and treatment application should be the
focus of clinicians in applying therapy for patients with
aRVD. Important points to remember include:
1. Clinical presentation remains one of the best measures
to predict favorable responses, and those patients most
likely to benefit (ie, those with cardiac disturbance man-
ifest by flash pulmonary edema, uncontrollable hyper-
tension, and rapidly declining renal function) are rela-
tively uncommon.
2. Surgery remains a viable and durable alternative for
treatment of the low-risk patient with aRVD and in
those patients poorly suited to RA-PTAS, such as those
with branch level disease, short main renal arteries,
multiple small renal arteries, and patients with associated
aortic aneurysmal or occlusive disease.
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